Arena Pharmaceuticals Announces R&D Leadership Transition
November 30 2020 - 4:05PM
Business Wire
- Paul D. Streck, M.D., Appointed as Senior Vice President,
Clinical Development and Chief Medical Officer, Bringing Successful
Development and Launch Experience Across Multiple Therapeutic
Indications
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced a
transition of its R&D leadership and the appointment of Paul D.
Streck, M.D., as Senior Vice President, Clinical Development and
Chief Medical Officer reporting to Amit Munshi, President and CEO.
The transition follows the retirement and resignation of Chris
Cabell, M.D., M.H.S., FACC, who served as the company’s Executive
Vice President, Head of Research and Development, and Chief Medical
Officer since June 2020. The change is effective as of December 1,
2020 and Dr. Cabell will remain an advisor to the Company.
Dr. Streck brings more than 25 years of experience in drug
development, regulatory and medical affairs leadership across both
large and small publicly traded biopharmaceutical companies, and a
track record of success with six global regulatory launches, five
IND’s and nine commercial product launches.
“Having Dr. Streck’s deep executive experience as a physician in
successful clinical development and medical affairs leadership
roles puts Arena in a stronger position as we move toward
completing late-stage clinical development into regulatory
submission and pre-commercial planning. His proven global
leadership roles across therapeutic indications provides for
seamless integration for the Company’s current and future clinical
and regulatory activities,” said Amit D. Munshi, Arena's President
and Chief Executive Officer.
“On behalf of Arena’s Board of Directors and management team, we
would like to thank Chris for his ability to step into a critical
role during an important time at our company. We wish him the best
in his future endeavors.”
Most recently, Dr. Streck served as Chief Medical Officer at
Alder Biopharmaceuticals, Inc., a publicly traded biotechnology
company, acquired by Lundbeck in late 2019. In this role, Dr.
Streck led clinical development, clinical operations, medical
affairs, regulatory, and safety/pharmacovigilance, and drove U.S.
approval of Vyepti®, a biologic medicine for prevention of
migraines. From 2017-2019, Dr. Streck was the Chief Medical Officer
of Insmed, Inc., a publicly traded biotechnology company. Previous
biopharmaceutical experience includes progressive roles at Amgen,
Shire, and GSK. He also has 10 years of experience in academic
medical practice.
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a singular purpose –
deliver our important medicines to patients.
In a rapidly changing global market, we work with a sense of
urgency every day to understand the needs of all our stakeholders,
identify bold, sometimes disruptive, ideas to get our medicines to
patients, and relentlessly execute until it's done.
ARENA - Care More. Act Differently.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include, without limitation, statements
about Dr. Streck’s expected contributions, Arena's position, drive,
portfolio, prioritization, financial position, team, and building
of the company. For such statements, Arena claims the protection of
the Private Securities Litigation Reform Act of 1995. Actual events
or results may differ materially from Arena's expectations. Factors
that could cause actual results to differ materially from the
forward-looking statements include those disclosed in Arena's
filings with the Securities and Exchange Commission. These
forward-looking statements represent Arena's judgment as of the
time of this release. Arena disclaims any intent or obligation to
update these forward-looking statements, other than as may be
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201130005870/en/
Corporate Contacts: Patrick Malloy Arena Pharmaceuticals,
Inc. Vice President, Investor Relations & Corporate
Communications pmalloy@arenapharm.com 847.987.4878
Megan E. Knight Arena Pharmaceuticals, Inc. Director, Investor
Relations mknight@arenapharm.com 858-210-3635
Arena Media Contact: LavoieHealthScience Katie Gallagher
kgallagher@lavoiehealthscience.com 617-792-3937
Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From Apr 2024 to May 2024
Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From May 2023 to May 2024